首页> Annals of oncology : official journal of the European Society for Medical Oncology> A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.

导出 LinkOut

翻译打印收藏纠错

第一作者： R,Wong

第一单位： Department of Medicine.

作者： R,Wong ^[1] ; D,Cunningham ^[2] ; Y,Barbachano ^[3] ; C,Saffery ^[1] ; J,Valle ^[4] ; T,Hickish ^[5] ; S,Mudan ^[6] ; G,Brown ^[7] ; A,Khan ^[6] ; A,Wotherspoon ^[8] ; A S,Strimpakos ^[1] ; J,Thomas ^[1] ; S,Compton ^[1] ; Y J,Chua ^[1] ; I,Chau ^[1]

作者单位： Department of Medicine. ^[1] Department of Medicine. Electronic address: david.cunningham@rmh.nhs.uk. ^[2] Department of Clinical Research and Development, Royal Marsden Hospital NHS Foundation Trust, Sutton. ^[3] Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester. ^[4] Department of Haematology and Oncology, Royal Bournemouth and Poole Hospital, Dorset. ^[5] Department of Academic Surgery. ^[6] Department of Diagnostic Imaging. ^[7] Department of Histopathology, Royal Marsden Hospital NHS Foundation Trust, London, UK. ^[8]